The Ethical Implications of Different Statistical Early-Stopping Rules for Randomized Clinical Trials
Dave Sackett is coming to the MUHC to learn how you reconcile the dilemma over whether to stop randomized clinical trials early, as soon as the best treatment for trial participants becomes qualitatively convincing, vs. keeping trials going until the best treatment for future patients outside the trial becomes indisputable and its effect-size (e.g., Relative Risk Reduction) becomes highly precise.
BIOGRAPHY: Dave Sackett is in his 8th career: reading, researching, DSMB-ing, writing and teaching about randomized clinical trials. Previous careers included 2 internal medicine residencies (ages 27 and 49), founding the Department of Clinical Epidemiology and Biostatistics at McMaster and the Centre for Evidence-Based Medicine at Oxford, practicing medicine in the US, Canada, and the UK, PI-ing 29 RCTs, and DSMB-ing 16 others.
Space is limited, so please send an RSVP to Susan Tardif (QAEP [at] muhc [dot] mcgill [dot] ca). A light lunch will be provided.